文献速递免疫规划传染病防控与疫情报告

恶性疟原虫疫苗抗原裂殖子表面蛋白1和RTS,S联合AS02佐剂在健康疟疾未暴露成人中的IIa期随机双盲安全性、免疫原性和效力试验

A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.
PubMed 文献 · Vaccine · 2024-04-06

2001年开展的双盲I/IIa期研究将60名健康疟疾未暴露成人按1:1:1:1随机分为四组,分别给予RTS,S/AS02与FMP1/AS02分开或同部位接种、单用FMP1/AS02或单用RTS,S/AS02,并按0、1、3月程序接种。结果显示同部位接种降低抗环子孢子抗体水平,但未影响耐受性、细胞免疫或CHMI模型中的效力;含RTS,S方案约30%无菌保护,FMP1/AS02单用组无无菌保护或寄生虫血症延迟。

要点

  • 同部位接种RTS,S与FMP1/AS02降低抗环子孢子抗体水平,分开接种或单用RTS,S抗体水平较高。
  • 含RTS,S方案在CHMI后约30%无菌保护,FMP1/AS02单用组无无菌保护或寄生虫血症延迟。
  • 所有疫苗组局部和全身不良事件多为轻中度,8天内消退。

核心结论

  • RTS,S与FMP1/AS02同部位接种降低抗RTS,S抗体,但未影响耐受性、细胞免疫或严格CHMI模型中的效力。
  • FMP1/AS02在子孢子攻击模型中无效力或无寄生虫血症延迟,不能排除其在疟疾流行人群中的效力,但肯尼亚儿童IIb期试验未显示对自然感染的保护效力。

研究设计与样本

  • 2001年开展的双盲I/IIa期随机试验,N=60名健康疟疾未暴露成人按1:1:1:1随机分为四组,每组N=15。
  • 四组分别为RTS,S/AS02与FMP1/AS02分开接种、同部位接种、单用FMP1/AS02或单用RTS,S/AS02,按0、1、3月程序三角肌半剂量接种。
  • 受种三剂疫苗者及N=11名未免疫对照通过控制性人类疟疾感染(CHMI)用同源恶性疟原虫3D7子孢子攻击。

主要发现

  • 所有疫苗组局部和全身不良事件多为轻中度,8天内消退。
  • 抗环子孢子抗体水平:同部位接种组35.0 µg/mL(95%CI 20.3-63),低于分开接种组57.4 µg/mL(95%CI 32.3-102)和单用RTS,S组62.0 µg/mL(95%CI 37.8-101.8)。
  • 接受RTS,S/AS02各组间RTS,S特异性淋巴细胞增殖反应和离体ELISpot CSP特异性干扰素-γ(IFN-γ)反应无差别。
  • 接受FMP1/AS02各组间抗FMP1抗体无差异。
  • CHMI后含RTS,S方案组约30%无菌保护,寄生虫血症出现时间延迟相当;FMP1/AS02单用组无无菌保护或寄生虫血症延迟。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • FMP1/AS02在子孢子攻击模型中无效力或无寄生虫血症延迟,不能排除其在疟疾流行人群中的效力。
  • 肯尼亚疟疾流行区儿童IIb期试验中FMP1/AS02未显示对自然感染的效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To improve the efficacy of Plasmodium falciparum malaria vaccine RTS,S/AS02, we conducted a study in 2001 in healthy, malaria-naïve adults administered RTS,S/AS02 in combination with FMP1, a recombinant merozoite surface-protein-1, C-terminal 42kD fragment. METHODS: A double-blind Phase I/IIa study randomized N = 60 subjects 1:1:1:1 to one of four groups, N = 15/group, to evaluate safety, immunogenicity, and efficacy of intra-deltoid half-doses of RTS,S/AS02 and FMP1/AS02 administered in the contralateral (RTS,S + FMP1-separate) or same (RTS,S + FMP1-same) sites, or FMP1/AS02 alone (FMP1-alone), or RTS,S/AS02 alone (RTS,S-alone) on a 0-, 1-, 3-month schedule. Subjects receiving three doses of vaccine and non-immunized controls (N = 11) were infected with homologous P. falciparum 3D7 sporozoites by Controlled Human Malaria Infection (CHMI). RESULTS: Subjects in all vaccination groups experienced mostly mild or moderate local and general adverse events that resolved within eight days. Anti-circumsporozoite antibody levels were lower when FMP1 and RTS,S were co-administered at the same site (35.0 µg/mL: 95 % CI 20.3-63), versus separate arms (57.4 µg/mL: 95 % CI 32.3-102) or RTS,S alone (62.0 µg/mL: 95 % CI: 37.8-101.8). RTS,S-specific lymphoproliferative responses and ex vivo ELISpot CSP-specific interferon-gamma (IFN-γ) responses were indistinguishable among groups receiving RTS,S/AS02. There was no difference in antibody to FMP1 among groups receiving FMP1/AS02. After CHMI, groups immunized with a RTS,S-containing regimen had ∼ 30 % sterile protection against parasitemia, and equivalent delays in time-to-parasitemia. The FMP1/AS02 alone group showed no sterile immunity or delay in parasitemia. CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection. CLINICALTRIALS: gov identifier: NCT01556945.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cummings JF, Polhemus ME, Kester KE, et al. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults. Vaccine. 2024. PMID: 38584058. doi:10.1016/j.vaccine.2024.03.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。